NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Forecast, Price & News

$0.08

0.00 (-2.35%)

(As of 02:01 PM ET)

Compare

Today's Range: $0.08
▼
$0.09
50-Day Range: $0.09
▼
$0.50
52-Week Range: $0.08
▼
$2.42

Volume: 16.26 million shs
Average Volume: 1.27 million shs
Market Capitalization: $9.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

RVL Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 3,117.5% Upside
$2.50 Price Target
Short Interest: Healthy
3.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.24
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.46) to ($0.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

634th out of 963 stocks

Pharmaceutical Preparations Industry

285th out of 451 stocks

3.3

Analyst's Opinion

Consensus Rating
RVL Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, RVL Pharmaceuticals has a forecasted upside of 3,117.5% from its current price of $0.08.
Amount of Analyst Coverage
RVL Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.21% of the float of RVL Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
RVL Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in RVL Pharmaceuticals has recently increased by 91.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
RVL Pharmaceuticals does not currently pay a dividend.
Dividend Growth
RVL Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVLP.

3.5

News and Social Media Coverage

News Sentiment
RVL Pharmaceuticals has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for RVL Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
55 people have searched for RVLP on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added RVL Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RVL Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of RVL Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 24.20% of the stock of RVL Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for RVL Pharmaceuticals are expected to grow in the coming year, from ($0.46) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RVL Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RVL Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RVL Pharmaceuticals has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About RVL Pharmaceuticals (NASDAQ:RVLP) Stock

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVLP Price History

30 days | 90 days | 365 days | Advanced Chart

RVLP Stock News Headlines

September 17, 2023 | americanbankingnews.com

Head to Head Review: RVL Pharmaceuticals (NASDAQ:RVLP) & Qualigen Therapeutics (NASDAQ:QLGN)

August 23, 2023 | finance.yahoo.com

Unmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLC

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 23, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 21, 2023 | markets.businessinsider.com

RVL Pharmaceuticals (RVLP) Gets a Buy from H.C. Wainwright

August 16, 2023 | benzinga.com

Crude Oil Falls Sharply; RVL Pharmaceuticals Shares Plummet

August 16, 2023 | msn.com

RVLP: Second Quarter Results

August 16, 2023 | marketwatch.com

RVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLP

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 16, 2023 | msn.com

RVL Pharmaceuticals shares fall after pricing $5M stock offering

August 16, 2023 | finance.yahoo.com

Downgrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near Term

August 16, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

August 15, 2023 | finance.yahoo.com

Q2 2023 RVL Pharmaceuticals PLC Earnings Call

August 14, 2023 | msn.com

RVLP: Revenue Dip Prompts Spending Reversal

August 14, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

July 20, 2023 | finance.yahoo.com

Insiders Re-Evaluate Their US$1.6m Stock Purchase As RVL Pharmaceuticals Falls To US$43m

July 5, 2023 | msn.com

RVL Pharma (NASDAQ:RVLP) Rises on Mulling A Strategic Transaction

July 5, 2023 | benzinga.com

RVL Pharmaceuticals shares are trading higher after the company said it has been considering certain strategic alternatives.

June 15, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting

June 2, 2023 | finance.yahoo.com

Shareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years ago

May 13, 2023 | finance.yahoo.com

Time To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Outlook

May 12, 2023 | finance.yahoo.com

RVLP: First Quarter Results

May 12, 2023 | msn.com

RVL Pharmaceuticals: Q1 Earnings Insights

May 12, 2023 | finance.yahoo.com

Q1 2023 RVL Pharmaceuticals PLC Earnings Call

May 10, 2023 | msn.com

Earnings Preview: RVL Pharmaceuticals

May 1, 2023 | finance.yahoo.com

RVLP: Selected for NewBeauty Award

May 1, 2023 | markets.businessinsider.com

Barclays Sticks to Their Buy Rating for RVL Pharmaceuticals (RVLP)

See More Headlines

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Company Calendar

Last Earnings: 8/14/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVLP
CUSIP: N/A
CIK: 1739426
Web: www.osmotica.com
Phone: (908) 809-1300
Fax: N/A
Employees: 125
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.50
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +2,841.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,690,000.00
Net Margins: -184.91%
Pretax Margin: -185.66%
Return on Equity: -130.22%
Return on Assets: -47.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.38
Quick Ratio: 0.36

Sales & Book Value

Annual Sales: $36.92 million
Price / Sales: 0.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 111,406,000
Free Float: 106,504,000
Market Cap: $9.47 million
Optionable: Optionable
Beta: 1.15

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Brian A. Markison (Age 64)
Chairman, Pres, CEO & Principal Financial Officer
Comp: $525k

Mr. James D. Schaub (Age 41)
Exec. VP & COO
Comp: $367.2k

Mr. Christopher A. Klein (Age 58)
Gen. Counsel & Sec.
Comp: $367.2k

Mr. Michael J. DePetris (Age 46)
Principal Accounting Officer

Mr. Jarret Miller
Exec. VP of HR

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RVLP Stock - Frequently Asked Questions

Should I buy or sell RVL Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVLP shares.
View RVLP analyst ratings or view top-rated stocks.
What is RVL Pharmaceuticals' stock price forecast for 2023?: 3 equities research analysts have issued twelve-month price objectives for RVL Pharmaceuticals' stock. Their RVLP share price forecasts range from $2.00 to $3.00. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 2,841.2% from the stock's current price.
View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts.
How have RVLP shares performed in 2023?: RVL Pharmaceuticals' stock was trading at $1.12 at the start of the year. Since then, RVLP stock has decreased by 92.4% and is now trading at $0.0850.
View the best growth stocks for 2023 here.
When is RVL Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RVLP earnings forecast.
How were RVL Pharmaceuticals' earnings last quarter?: RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). The firm earned $8.26 million during the quarter, compared to analyst estimates of $10.38 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%.
What is RVL Pharmaceuticals' stock symbol?: RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP."

Who are RVL Pharmaceuticals' major shareholders?: RVL Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (1.52%), Worth Venture Partners LLC (0.28%) and Citadel Advisors LLC (0.00%).
How do I buy shares of RVL Pharmaceuticals?: Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is RVL Pharmaceuticals' stock price today?: One share of RVLP stock can currently be purchased for approximately $0.09.
How much money does RVL Pharmaceuticals make?: RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $9.47 million and generates $36.92 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.
How many employees does RVL Pharmaceuticals have?: The company employs 125 workers across the globe.
How can I contact RVL Pharmaceuticals?: RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com.

This page (NASDAQ:RVLP) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial